On the afternoon of February 22, a warm and friendly meeting took place at the IMP2 Vinh Loc factory cluster in Ho Chi Minh City between Imexpharm’s leadership team, Board members, and its strategic investors.
During this meeting, the Executive Board and representatives of the Board of Directors spent most of the time consulting with investors and answering their questions regarding Imexpharm's policies and development strategies for the coming years.
Additionally, during this gathering, Imexpharm proudly introduced its third new factory cluster to the investors. The IMP2 High-Tech Antibiotics Factory, with an investment of over VND 180 billion, was started in September 2016 and completed in October 2018, specializing in Penicillin products.
The factory recently received EU-GMP certification from the Portuguese Ministry of Health on January 2, 2019. This was an impressive experience for the investors and strategic shareholders, who had the opportunity to visit one of the most modern pharmaceutical factories in Vietnam.
For Imexpharm, this factory stands as a testament to the company’s commitment to the trust placed in it by its investors from the very beginning. The Imexpharm team worked tirelessly, even during holidays and Tết holidays, to complete the factory as quickly as possible and at the lowest cost.
.jpg)
The favorable conditions Imexpharm currently enjoys were created by the long-term strategy of the Executive Board and Board of Directors, along with the experience gained from building previous EU-GMP certified factories. Above all, the trust, support, and collaboration from investors and strategic shareholders have always been instrumental to Imexpharm’s success.